Tag: deaths
-
December 2021 JAK Inhibitors Drug Class Label Changes: More Warnings and Use Restrictions
Risks of Cancers, Blood Clots, Heart Problems, and Deaths Associated with Xeljanz, Olumiant, and Rinvoq (Posted by Tom Lamb at Drug Injury Watch) As background, in September 2021 the FDA announced that it was requiring…
-
Xeljanz: FDA Warnings Updated: There are Higher Rates of Blood Clots and Deaths for Both Doses of Xeljanz, Now
JAK Inhibitors Xeljanz, Olumiant, and Rinvoq Get Drug Label Changes and Drug Use Limitations in September 2021 (Posted by Tom Lamb at Drug Injury Watch) On September 1, 2021, the FDA released this alerting news…
-
Report on FDA Belviq Recall Decision Provides New Information About Excess Cancers Risks
Belviq Safety Data Review Found Higher Rates of Colorectal Cancer, Pancreatic Cancer, and Lung Cancer (Posted by Tom Lamb at DrugInjuryWatch.com) The FDA's decision to request that the pharmaceutical company Eisai recall…
-
Lemtrada Use Restrictions Issued By EMA’s Pharmacovigilance Risk Assessment Committee Due To Safety Issues
Action Due To Reports Of Lemtrada Side Effects Including Deaths Related To Immune Complications And Heart Or Circulatory Disorders (Posted by Tom Lamb at DrugInjuryWatch.com) In late October 2019 the Pharmacovigilance Risk…
-
Uloric Side Effects Lead To An Increased Risk of Patient Cardiovascular Deaths, Says Health Canada
Drug Safety Warning: Watch For Myocardial Infarction, Stroke, And Cardiac Failure In People Who Are Taking Uloric (Posted by Tom Lamb at DrugInjuryWatch.com) In early November 2019 Health Canada warned that in…
-
Xeljanz Warning For Increased Risk Of Blood Clots And Death With Higher Dose Used For Ulcerative Colitis
"Black Box Warning" For Xeljanz 10 mg Twice Daily Dose Required By FDA In July 2019 Follows Regulatory Action In Europe (Posted by Tom Lamb at DrugInjuryWatch.com) A Xeljanz FDA Drug Safety…
-
Uloric Use By Patients With Major Cardiovascular Disease Associated With Higher Risk Of Deaths
New Drug Safety Warning: Uloric Should Be Avoided When There Is Prior Myocardial Infarction, Stroke, Or Unstable Angina (Posted by Tom Lamb at DrugInjuryWatch.com) From this Drug Safety Update issued July 17,…
-
Xeljanz Recommended Dosage For Ulcerative Colitis Patients May Increase Risk Of Pulmonary Embolism
FDA Is Reviewing Safety Of Xeljanz 10 mg Twice-Daily Dose Of This JAK Inhibitor, According to February 2019 News Reports (Posted by Tom Lamb at DrugInjuryWatch.com) UPDATE: FDA Drug Safety Communication: "Safety…
-
Gout Drug Uloric Recall By FDA Requested In June 2018 Public Citizen Petition Letter
Consumer Group Contends That The Evidence Of Harmful Uloric Side Effects Outweighs Any Real Benefit To Patients (Posted by Tom Lamb at DrugInjuryWatch.com) The FDA should order Takeda Pharmaceuticals to immediately withdraw from…
-
Viberzi – Pancreatitis Side Effects Can Develop At Any Time While Taking This IBS Drug, According To FDA Safety Warning
Severe Cases Of Pancreatitis And Sphincter Of Oddi Spasm Reported Even After Just The First Dose Of Viberzi, With Some Resulting In Patient Deaths (Posted by Tom Lamb at DrugInjuryWatch.com) In March…